MediWound (NASDAQ:MDWD) Issues Earnings Results

Key Points

• MediWound missed quarterly earnings expectations: It reported an EPS loss of $0.77 versus the $0.76 consensus, while revenue of $3.09 million exceeded estimates of $2.59 million.
• EscharEx development remains on schedule, with the Phase III VALUE trial targeting enrollment completion and interim sample-size reassessment by the end of Q1 2027. The company raised its estimated U.S. peak annual sales opportunity to $1.05 billion after including pressure ulcers.
• Financial pressure persists despite commercial progress: First-half cash fell to about $36 million after $20 million in cash burn, and second-quarter revenue declined year over year. MediWound maintained 2026 revenue guidance of $24 million–$26 million, with much of the expected contribution weighted toward the second half.

MediWound (NASDAQ:MDWD - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.01), Zacks reports. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The business had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million.

Here are the key takeaways from MediWound's conference call:

• EscharEx’s VALUE Phase III trial remains on track, with interim sample-size reassessment and enrollment completion targeted by the end of Q1 2027. The company says nearly all of the approximately 40 sites are recruiting.
• MediWound expanded its estimated U.S. peak annual sales opportunity for EscharEx to $1.05 billion after including pressure ulcers, and plans to start a 50-patient diabetic foot ulcer study and a small pressure-ulcer investigator-initiated study in Q4 2026.
• NexoBrid’s U.S. commercial adoption continued to improve, with Vericel reporting record quarterly revenue, hospital unit sales and ordering centers; approximately 80 U.S. burn centers have ordered the product since launch.
• The new master service agreement with Vericel is expected to begin contributing revenue in the second half of 2026, including development programs targeting blast and friction injuries. MediWound reaffirmed 2026 revenue guidance of $24 million–$26 million, weighted heavily toward the second half.
• Financial performance weakened in the first half: Q2 revenue fell to $3.1 million from $5.7 million year over year, while cash and deposits declined to approximately $36 million from $54 million at year-end 2025 after $20 million of first-half cash burn. R&D spending is expected to remain elevated as the VALUE trial advances, and expanded-facility commercial supply is not expected until the second half of 2027.

MediWound Stock Performance

MDWD traded down $0.38 during midday trading on Thursday, reaching $13.53. 62,264 shares of the company were exchanged, compared to its average volume of 63,044. The stock has a market capitalization of $173.86 million, a P/E ratio of -5.99 and a beta of 0.15. The stock's 50-day simple moving average is $14.36 and its 200 day simple moving average is $15.99. MediWound has a one year low of $13.46 and a one year high of $20.30.

Insider Transactions at MediWound

In other news, Director David Morton Fox bought 3,537 shares of the stock in a transaction on Monday, June 1st. The stock was purchased at an average price of $14.11 per share, with a total value of $49,907.07. Following the completion of the purchase, the director owned 22,283 shares of the company's stock, valued at approximately $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 9.20% of the company's stock.

Institutional Investors Weigh In On MediWound

Large investors have recently modified their holdings of the business. Quarry LP acquired a new position in shares of MediWound in the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets boosted its stake in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 723 shares during the period. Russell Investments Group Ltd. raised its position in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 649 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after acquiring an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new position in MediWound during the 4th quarter worth approximately $109,000. 46.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MDWD has been the topic of several research analyst reports. Oppenheimer reaffirmed an "outperform" rating and set a $32.00 price objective (down from $33.00) on shares of MediWound in a research note on Wednesday, May 27th. HC Wainwright reiterated a "buy" rating and set a $36.00 price target on shares of MediWound in a research report on Thursday, May 28th. Weiss Ratings restated a "sell (d-)" rating on shares of MediWound in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday, May 30th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $34.00.

MediWound Company Profile

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source